Can retatrutide be compounded?

This question arrives constantly, and the reason is obvious: retatrutide has enormous consumer search interest well ahead of any approval, and a large gray market has grown to meet it. That market is being enforced against. If you are a licensed pharmacy weighing whether there is a compliant path here, the answer is unusually clean — there isn’t one, and the ambiguity that exists around some other peptides does not exist around this one.

Why it fails the 503A test

Section 503A of the Federal Food, Drug, and Cosmetic Act permits a compounding pharmacy to use a bulk drug substance only if it satisfies at least one of three conditions. Retatrutide satisfies none.

The same analysis holds for 503B outsourcing facilities, which draw from their own separate bulks list. Retatrutide is not on that one either.

This is a meaningfully different situation from the twelve peptides the FDA removed from the Category 2 “do not compound” list in April 2026. Those substances are in an unresolved gap — no longer flagged, not yet listed — and reasonable people are arguing about what that permits. Retatrutide was never in that process. It is a drug awaiting approval, and compounding a copy of an unapproved drug is not a gap in the rules. It is outside them.

The September 2025 warning letters

In September 2025 the FDA issued warning letters to six companies — five in the United States and one in Germany — over the sale of compounded or marketed retatrutide.

The letters are worth reading closely for one reason in particular: the agency addressed the “research use only” labeling convention head-on, treating it as a legal fiction where products were packaged with human dosing instructions and sold directly to consumers. The label on the vial did not determine how the agency characterized the product. How the product was presented, dosed, and sold did.

What about the approval timeline?

Retatrutide remains in late-stage development. Reporting on the sponsor’s expected filing points to a new drug application in late 2026 or early 2027, with commercial availability projected for 2027 to 2028. Those are projections, not commitments, and they are outside the FDA’s control as much as anyone’s.

What matters operationally is that approval, whenever it comes, would not retroactively legitimize anything compounded beforehand — and an approved product is generally less available for compounding, not more, because compounding essentially a copy of a commercially available approved drug runs into a separate restriction under section 503A.

Where Meridian stands

We build cold chain packaging for licensed compounding pharmacies and the telehealth companies they fill for. We do not manufacture, sell, or distribute peptides, and we are not the right party to give you a legal determination — a compounding attorney is.

We publish this because pharmacies ask us about shipping preparations we do not think they should be making, and the useful answer to that question is not a packout recommendation. If a preparation cannot lawfully be compounded, the packaging question is the least of the exposure.